Literature DB >> 30244854

MET-UBE2H Fusion as a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma.

You-Cai Zhu1, Wen-Xian Wang2, Zheng-Bo Song2, Qu-Xia Zhang3, Chun-Wei Xu4, Gang Chen3, Wu Zhuang5, Tangfeng Lv6, Yong Song6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30244854     DOI： 10.1016/j.jtho.2018.05.009

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

1.  Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.

Authors:  Félix Blanc-Durand; Raafat Alameddine; Anthony J Iafrate; Danh Tran-Thanh; Ying-Chun Lo; Normand Blais; Bertrand Routy; Mustapha Tehfé; Charles Leduc; Phillipe Romeo; Phillipe Stephenson; Marie Florescu
Journal:  Oncologist       Date:  2020-09-08

2.  Ubiquitin Conjugating Enzyme E2 H (UBE2H) Is Linked to Poor Outcomes and Metastasis in Lung Adenocarcinoma.

Authors:  Meng-Chi Yen; Kuan-Li Wu; Yu-Wei Liu; Yung-Yun Chang; Chao-Yuan Chang; Jen-Yu Hung; Ying-Ming Tsai; Ya-Ling Hsu
Journal:  Biology (Basel)       Date:  2021-04-28

3.  Identification of a Ubiquitination-Related Gene Risk Model for Predicting Survival in Patients With Pancreatic Cancer.

Authors:  Hao Zuo; Luojun Chen; Na Li; Qibin Song
Journal:  Front Genet       Date:  2020-12-22       Impact factor: 4.599

4.  Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report.

Authors:  Xia Wang; Weiwei Peng; Zhimin Zeng; Jing Cai; Anwen Liu
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

5.  Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion.

Authors:  Qing Ma; Lingping Kong; Diansheng Zhong
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

6.  Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report.

Authors:  Lian-Fang Liu; Jia-Ying Deng; Analyn Lizaso; Jing Lin; Si Sun
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

7.  Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion.

Authors:  Lanzi Ou; Yicong Tang; Yanming Deng; Lijie Guo; Qingqing He; Tingting He; Weineng Feng
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

8.  Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report.

Authors:  Junfang Liu; Lijun Shen; Yunyao Qian; Yunpeng Liu; Minhong Su; Li Yi
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

9.  [Chinese Expert Consensus on Next Generation Sequencing Diagnosis 
for Non-small Cell Lung Cancer (2020 Edition)].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.